Schneider E, Darkin S J, Lawson P A, Ching L M, Ralph R K, Baguley B C
Department of Cellular and Molecular Biology, University of Auckland, New Zealand.
Eur J Cancer Clin Oncol. 1988 Nov;24(11):1783-90. doi: 10.1016/0277-5379(88)90082-x.
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (NSC 601316) is a DNA intercalating experimental antitumour agent which is curative against the Lewis lung carcinoma in mice. Its action has been compared with amsacrine, its inactive isomer oAMSA, the solid tumour active derivative CI-921 (NSC 343499), a C-6 methylene chain-linked bisacridine (NSC 210733), 9-aminoacridine and quinacrine. All compounds inhibited the unknotting of phage P4 DNA by topoisomerase II in nuclear extracts prepared from L1210 cells. NSC 601316 inhibited growth of cultured L1210, P388, P/AMSA (P388 resistant to amsacrine) and P/ACTD (resistant to actinomycin D) cell lines at concentrations of 87, 150, 2020 and 150 nM respectively. A 1 h drug exposure to 0.85 microM NSC 601316 killed 50% of L1210 cells. L1210 cells treated for 1 h with NSC 601316 accumulated DNA breaks and protein-DNA cross-links. There was a good correlation between DNA breakage and cytotoxicity, but the relationship between drug concentration and number of protein-DNA cross-links was non-linear and differed from that of amsacrine and CI-921. There was also a positive correlation between the degree of cross-resistance of P/AMSA cells (which have altered topoisomerase II function) and ability to induce DNA breakage or protein-DNA complexes. The results suggest that topoisomerase II is the target of action of NSC 601316.
N-[2-(二甲基氨基)乙基]吖啶-4-甲酰胺(NSC 601316)是一种DNA嵌入型实验性抗肿瘤药物,对小鼠Lewis肺癌具有治愈作用。已将其作用与安吖啶、其无活性异构体oAMSA、实体瘤活性衍生物CI-921(NSC 343499)、一种C-6亚甲基链连接的双吖啶(NSC 210733)、9-氨基吖啶和喹吖因进行了比较。所有化合物均抑制从L1210细胞制备的核提取物中拓扑异构酶II对噬菌体P4 DNA的解结作用。NSC 601316分别在87、150、2020和150 nM的浓度下抑制培养的L1210、P388、P/AMSA(对安吖啶耐药的P388)和P/ACTD(对放线菌素D耐药)细胞系的生长。将L1210细胞暴露于0.85 microM NSC 601316 1小时可杀死50%的细胞。用NSC 601316处理L1210细胞1小时会积累DNA断裂和蛋白质-DNA交联。DNA断裂与细胞毒性之间存在良好的相关性,但药物浓度与蛋白质-DNA交联数量之间的关系是非线性的,且与安吖啶和CI-921不同。P/AMSA细胞(其拓扑异构酶II功能已改变)的交叉耐药程度与诱导DNA断裂或蛋白质-DNA复合物的能力之间也存在正相关。结果表明拓扑异构酶II是NSC 601316的作用靶点。